These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 25388535)

  • 1. Bile acid derivatives as ligands of the farnesoid x receptor: molecular determinants for bile acid binding and receptor modulation.
    Gioiello A; Cerra B; Mostarda S; Guercini C; Pellicciari R; Macchiarulo A
    Curr Top Med Chem; 2014; 14(19):2159-74. PubMed ID: 25388535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond bile acids: targeting Farnesoid X Receptor (FXR) with natural and synthetic ligands.
    Carotti A; Marinozzi M; Custodi C; Cerra B; Pellicciari R; Gioiello A; Macchiarulo A
    Curr Top Med Chem; 2014; 14(19):2129-42. PubMed ID: 25388537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis.
    Ho PP; Steinman L
    Proc Natl Acad Sci U S A; 2016 Feb; 113(6):1600-5. PubMed ID: 26811456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Yangonin protects against cholestasis and hepatotoxity via activation of farnesoid X receptor in vivo and in vitro.
    Gao X; Fu T; Wang C; Ning C; Liu K; Liu Z; Sun H; Ma X; Huo X; Yang X; Zou M; Meng Q
    Toxicol Appl Pharmacol; 2018 Jun; 348():105-116. PubMed ID: 29660435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress and challenges of selective Farnesoid X Receptor modulation.
    Massafra V; Pellicciari R; Gioiello A; van Mil SWC
    Pharmacol Ther; 2018 Nov; 191():162-177. PubMed ID: 29933033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH).
    Fiorucci S; Biagioli M; Sepe V; Zampella A; Distrutti E
    Expert Opin Investig Drugs; 2020 Jun; 29(6):623-632. PubMed ID: 32552182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Farnesoid X receptor modulators 2014-present: a patent review.
    Sepe V; Distrutti E; Fiorucci S; Zampella A
    Expert Opin Ther Pat; 2018 May; 28(5):351-364. PubMed ID: 29649907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Farnesoid X receptor agonists for primary biliary cirrhosis.
    Lindor KD
    Curr Opin Gastroenterol; 2011 May; 27(3):285-8. PubMed ID: 21297469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Farnesoid X receptor: from medicinal chemistry to clinical applications.
    Fiorucci S; Mencarelli A; Distrutti E; Zampella A
    Future Med Chem; 2012 May; 4(7):877-91. PubMed ID: 22571613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural Insight into the Binding Mode of FXR and GPBAR1 Modulators.
    Di Leva FS; Di Marino D; Limongelli V
    Handb Exp Pharmacol; 2019; 256():111-136. PubMed ID: 31161298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Short Review on Obeticholic Acid: An Effective Modulator of Farnesoid X Receptor.
    Narayanan AK; Surendran S; Balakrishnan D; Gopalakrishnan U; Malick S; Valsan A; Philips CA; Watson CJE
    Curr Rev Clin Exp Pharmacol; 2024; 19(3):225-233. PubMed ID: 38708917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor.
    Pineda Torra I; Claudel T; Duval C; Kosykh V; Fruchart JC; Staels B
    Mol Endocrinol; 2003 Feb; 17(2):259-72. PubMed ID: 12554753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation on bile acid receptor regulators. Discovery of cholanoic acid derivatives with dual G-protein coupled bile acid receptor 1 (GPBAR1) antagonistic and farnesoid X receptor (FXR) modulatory activity.
    Sepe V; Renga B; Festa C; Finamore C; Masullo D; Carino A; Cipriani S; Distrutti E; Fiorucci S; Zampella A
    Steroids; 2016 Jan; 105():59-67. PubMed ID: 26607331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anthranilic acid derivatives as novel ligands for farnesoid X receptor (FXR).
    Merk D; Gabler M; Gomez RC; Flesch D; Hanke T; Kaiser A; Lamers C; Werz O; Schneider G; Schubert-Zsilavecz M
    Bioorg Med Chem; 2014 Apr; 22(8):2447-60. PubMed ID: 24685112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The evolution of farnesoid X, vitamin D, and pregnane X receptors: insights from the green-spotted pufferfish (Tetraodon nigriviridis) and other non-mammalian species.
    Krasowski MD; Ai N; Hagey LR; Kollitz EM; Kullman SW; Reschly EJ; Ekins S
    BMC Biochem; 2011 Feb; 12():5. PubMed ID: 21291553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bile salts in control of lipid metabolism.
    Schonewille M; de Boer JF; Groen AK
    Curr Opin Lipidol; 2016 Jun; 27(3):295-301. PubMed ID: 27031274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Pharmacology of Bile Acids and Their Receptors.
    Fiorucci S; Distrutti E
    Handb Exp Pharmacol; 2019; 256():3-18. PubMed ID: 31201555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bile acids and their nuclear receptor FXR: Relevance for hepatobiliary and gastrointestinal disease.
    Gadaleta RM; van Mil SW; Oldenburg B; Siersema PD; Klomp LW; van Erpecum KJ
    Biochim Biophys Acta; 2010 Jul; 1801(7):683-92. PubMed ID: 20399894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting FXR in cholestasis: hype or hope.
    Fiorucci S; Distrutti E; Ricci P; Giuliano V; Donini A; Baldelli F
    Expert Opin Ther Targets; 2014 Dec; 18(12):1449-59. PubMed ID: 25200104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ligand binding and heterodimerization with retinoid X receptor α (RXRα) induce farnesoid X receptor (FXR) conformational changes affecting coactivator binding.
    Wang N; Zou Q; Xu J; Zhang J; Liu J
    J Biol Chem; 2018 Nov; 293(47):18180-18191. PubMed ID: 30275017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.